Amedisys Company Insiders
AMED Stock | USD 92.64 0.07 0.08% |
Amedisys' insiders are aggressively selling. The analysis of insiders' sentiment of trading Amedisys stock suggests that all insiders are panicking at this time. Amedisys employs about 19 K people. The company is managed by 17 executives with a total tenure of roughly 35 years, averaging almost 2.0 years of service per executive, having 1117.65 employees per reported executive.
Paul Kusserow CEO CEO and President and Director |
Michael North President Senior Vice President - Operations |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2023-03-03 | Michael Paul North | Disposed 5908 @ 86.43 | View | ||
2022-06-23 | Denise M Bohnert | Disposed 557 @ 115 | View | ||
2022-03-29 | David L Kemmerly | Disposed 2500 @ 177.31 | View |
Monitoring Amedisys' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Amedisys |
Amedisys' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amedisys' future performance. Based on our forecasts, it is anticipated that Amedisys will maintain a workforce of about 19000 employees by April 2025.Amedisys Management Team Effectiveness
The company has return on total asset (ROA) of 0.0624 % which means that it generated a profit of $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0332 %, meaning that it created $0.0332 on every $100 dollars invested by stockholders. Amedisys' management efficiency ratios could be used to measure how well Amedisys manages its routine affairs as well as how well it operates its assets and liabilities. At present, Amedisys' Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.04, whereas Return On Assets are forecasted to decline to 0.01. At present, Amedisys' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 92.4 M, whereas Net Tangible Assets are projected to grow to (288.1 M).The current year's Net Income Applicable To Common Shares is expected to grow to about 143.2 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 23.8 M.
Amedisys Workforce Comparison
Amedisys is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 274,548. Amedisys holds roughly 19,000 in number of employees claiming about 7% of equities under Health Care industry.
Amedisys Profit Margins
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.52 | 0.4334 |
|
|
Amedisys Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amedisys insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amedisys' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amedisys insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2025-03-01 | 0.75 | 6 | 8 | 95,467 | 9,211 |
2024-12-01 | 0.5 | 1 | 2 | 10,421 | 14,586 |
2024-09-01 | 0.5 | 1 | 2 | 2,179 | 210.00 |
2024-06-01 | 2.6667 | 8 | 3 | 13,424 | 2,849 |
2024-03-01 | 1.75 | 7 | 4 | 98,702 | 6,551 |
2023-12-01 | 0.2 | 1 | 5 | 11,237 | 40,552 |
2023-06-01 | 4.6667 | 14 | 3 | 232,098 | 16,724 |
2023-03-01 | 2.125 | 17 | 8 | 99,314 | 24,861 |
2022-06-01 | 0.7 | 7 | 10 | 9,128 | 6,672 |
2022-03-01 | 1.6154 | 21 | 13 | 144,395 | 108,203 |
2021-12-01 | 0.5 | 1 | 2 | 1,000.00 | 1,200 |
2021-06-01 | 0.5789 | 11 | 19 | 9,667 | 17,951 |
2021-03-01 | 0.661 | 39 | 59 | 123,347 | 78,433 |
2020-12-01 | 0.1935 | 6 | 31 | 3,338 | 10,260 |
2020-09-01 | 0.14 | 7 | 50 | 508,635 | 760,284 |
2020-06-01 | 0.2931 | 17 | 58 | 45,392 | 82,985 |
2020-03-01 | 0.5738 | 35 | 61 | 160,189 | 145,868 |
2019-12-01 | 0.3529 | 6 | 17 | 8,389 | 26,256 |
2019-06-01 | 0.4444 | 16 | 36 | 40,907 | 85,855 |
2019-03-01 | 1.5455 | 34 | 22 | 372,156 | 70,678 |
2018-12-01 | 0.381 | 16 | 42 | 116,545 | 182,171 |
2018-09-01 | 0.3333 | 3 | 9 | 42,626 | 5,989 |
2018-06-01 | 0.4194 | 13 | 31 | 41,813 | 2,509,893 |
2018-03-01 | 1.0625 | 17 | 16 | 158,678 | 70,038 |
2017-12-01 | 3.0 | 3 | 1 | 17,656 | 7,866 |
2017-09-01 | 0.8571 | 6 | 7 | 4,126 | 5,217 |
2017-06-01 | 0.4483 | 13 | 29 | 40,028 | 123,635 |
2017-03-01 | 2.3636 | 26 | 11 | 364,839 | 61,150 |
2016-12-01 | 0.1429 | 1 | 7 | 6,875 | 29,597 |
2016-06-01 | 0.3617 | 17 | 47 | 38,765 | 188,997 |
2016-03-01 | 3.3333 | 10 | 3 | 185,967 | 12,251 |
2015-12-01 | 0.2727 | 3 | 11 | 130,000 | 694,303 |
2015-09-01 | 0.5 | 1 | 2 | 3,000 | 23,063 |
2015-06-01 | 1.4444 | 13 | 9 | 63,814 | 17,249 |
2015-03-01 | 0.0476 | 1 | 21 | 75,000 | 23,267 |
2014-12-01 | 1.0 | 3 | 3 | 350,000 | 11,355 |
2014-09-01 | 1.5 | 6 | 4 | 46,674 | 2,500 |
2014-06-01 | 1.875 | 15 | 8 | 768,818 | 13,568 |
2014-03-01 | 0.4286 | 3 | 7 | 10,090 | 2,263 |
2013-12-01 | 2.0 | 12 | 6 | 1,600,295 | 11,139 |
2013-09-01 | 0.8333 | 5 | 6 | 55,955 | 1,721 |
2013-06-01 | 1.1429 | 16 | 14 | 489,791 | 145,741 |
2012-12-01 | 0.5 | 1 | 2 | 1,334 | 2,041 |
2012-09-01 | 0.8 | 4 | 5 | 39,592 | 2,500 |
2012-06-01 | 2.8 | 28 | 10 | 171,732 | 55,144 |
2012-03-01 | 2.0 | 6 | 3 | 65,099 | 46,108 |
2011-12-01 | 3.5 | 7 | 2 | 53,648 | 13,560 |
2011-06-01 | 0.8125 | 13 | 16 | 135,186 | 59,628 |
2011-03-01 | 1.0 | 3 | 3 | 31,390 | 3,567 |
2010-09-01 | 1.875 | 15 | 8 | 55,824 | 30,759 |
2010-06-01 | 0.8333 | 15 | 18 | 47,539 | 20,379 |
2010-03-01 | 0.4706 | 8 | 17 | 49,817 | 63,065 |
2009-12-01 | 0.4167 | 5 | 12 | 18,300 | 48,911 |
2009-09-01 | 0.5833 | 7 | 12 | 31,180 | 104,508 |
2009-06-01 | 1.4 | 7 | 5 | 67,702 | 8,236 |
2009-03-01 | 1.5 | 12 | 8 | 123,088 | 69,469 |
2008-12-01 | 2.0 | 6 | 3 | 10,285 | 2,600 |
2008-09-01 | 0.2941 | 5 | 17 | 13,600 | 73,200 |
2008-06-01 | 1.2143 | 34 | 28 | 125,032 | 77,514 |
2008-03-01 | 0.75 | 6 | 8 | 41,484 | 26,600 |
2007-12-01 | 0.4231 | 11 | 26 | 44,207 | 155,156 |
2007-09-01 | 5.0 | 5 | 1 | 13,335 | 6,667 |
2007-06-01 | 1.375 | 11 | 8 | 87,697 | 64,286 |
2007-03-01 | 0.5 | 5 | 10 | 22,000 | 31,733 |
2006-12-01 | 1.0 | 1 | 1 | 13,334 | 0.00 |
2006-09-01 | 1.6667 | 5 | 3 | 12,273 | 12,697 |
2006-03-01 | 4.75 | 19 | 4 | 40,702 | 16,812 |
2005-12-01 | 0.5 | 6 | 12 | 22,166 | 44,657 |
2005-09-01 | 0.3488 | 15 | 43 | 99,395 | 276,972 |
2005-06-01 | 0.3 | 3 | 10 | 16,444 | 58,531 |
2005-03-01 | 1.1667 | 7 | 6 | 90,932 | 28,061 |
2004-12-01 | 1.5 | 3 | 2 | 116,667 | 1,485 |
2004-09-01 | 0.6818 | 15 | 22 | 50,000 | 150,330 |
2004-03-01 | 0.0345 | 2 | 58 | 15,291 | 667,641 |
2003-12-01 | 0.0909 | 2 | 22 | 40,000 | 165,527 |
2003-09-01 | 12.0 | 12 | 1 | 396,394 | 72,400 |
Amedisys Notable Stakeholders
An Amedisys stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amedisys often face trade-offs trying to please all of them. Amedisys' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amedisys' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Richard Ashworth | CEO President | Profile | |
Paul Kusserow | CEO and President and Director | Profile | |
Michael North | Senior Vice President - Operations | Profile | |
Nick Muscato | Vice President of Strategic Finance | Profile | |
Scott CPA | COO, VP | Profile | |
John Nugent | Chief Officer | Profile | |
Pete Hartley | CTO Systems | Profile | |
Kendra Kimmons | VP Relations | Profile | |
Jennifer Griffin | Chief Secretary | Profile | |
Janet Britt | VP Collections | Profile | |
Francis Mayer | Senior Development | Profile | |
Keith Blanchard | Acting Officer | Profile | |
Allyson Guidroz | Chief Officer | Profile | |
Scott Ginn | Chief Accounting Officer | Profile | |
Denise Bohnert | Chief Officer | Profile | |
Caitlin Franklin | Acting Officer | Profile | |
Adam Holton | Chief Officer | Profile |
About Amedisys Management Performance
The success or failure of an entity such as Amedisys often depends on how effective the management is. Amedisys management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amedisys management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amedisys management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.05 | 0.06 | |
Return On Capital Employed | 0.06 | 0.06 | |
Return On Assets | 0.02 | 0.01 | |
Return On Equity | 0.04 | 0.04 |
Please note, the presentation of Amedisys' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amedisys' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amedisys' management manipulating its earnings.
Amedisys Workforce Analysis
Traditionally, organizations such as Amedisys use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amedisys within its industry.Amedisys Manpower Efficiency
Return on Amedisys Manpower
Revenue Per Employee | 123.6K | |
Revenue Per Executive | 138.1M | |
Net Income Per Employee | 2K | |
Net Income Per Executive | 2.2M | |
Working Capital Per Employee | 6.2K | |
Working Capital Per Executive | 6.9M |
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |